Lymphocytes express two STIM isoforms, STIM1 and STIM2, which mediate store-operated Ca2+ entry in B and T cells.
Ca2+-release-activated Ca2+ (CRAC) channels arising from Orai1 proteins mediate store-operated Ca2+ entry when STIM1 proteins sense Ca2+-depletion of the smooth endoplasmic reticulum [1,2].
They differ, however, in whether under physiological conditions they effectively allow only Ca2+ to pass [e.g., voltage-gated Ca2+ channels (Cav) and the Orai proteins that mediate store-operated Ca2+ entry] or also allow other cations to pass [e.g., IP3 receptors (IP3R), ryanodine receptors (RyR), and nicotinic acetylcholine receptors].
Activation of Orai1/CRACM1 channels (though not discovered at that time and thus termed capacitative Ca2+ entry channels) by cADPR via RyR-mediated store depletion was described for DT40B lymphoma cells lacking expression of all three subtypes of IP3 receptors [ 34].
This finding would be compatible with defects at the levels of ion channels mediating the store operated calcium influx such as TRPC1 or TRPC4 channels.
Therefore, mRCC cells are endowed with all the molecular candidates to mediate the store-dependent Ca2+ influx induced by CPA, thapsigargin, and ionomycin.
Ca2+ release-activated Ca2+ channels (CRACs) are also located in plasma membrane and mediate the store-operated calcium channel entry (SOCE) [ 29].
RESULTS: In this study, we investigated the role of Ca2+ release-activated Ca2+ (CRAC) channels and the Ca2+ influx they mediate, called store-operated calcium entry (SOCE), in antitumour immunity.
A major calcium pathway is mediated by store-operated channels (SOCs).
Other studies have shown that wild-type APP is not directly involved in modulating calcium stores but does mediate the increase in store size that is seen with certain PS mutants and PS deficiency [39].
In aggregate, we introduce a novel pharmacological approach to distinguish between second messenger-gated TRPC-mediated and store-operated, Orai-mediated Ca2+ entry using selective pyrazole compounds including Pyr10 as a novel TRPC3-selective inhibitor.
